|
First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system. |
|
|
Patents, Royalties, Other Intellectual Property - Patent for HSV1TK+FLT3L therapy |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - TrueVision |
Consulting or Advisory Role - TrueVision |
|
|
Research Funding - Northwest Biotherapeutics; Tocagen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Tocagen |
Consulting or Advisory Role - Abbvie; Tocagen |
Research Funding - Genentech/Roche; Vascular Biogenics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - EpicentRx (Inst) |
|
|
Consulting or Advisory Role - Innocrin Pharma |
Research Funding - Innocrin Pharma |
Patents, Royalties, Other Intellectual Property - patent (Inst) |
|
|
No Relationships to Disclose |
|
Sandra Ines Camelo-Piragua |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amgen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |